The Management Team of the Company has many years of experience in the field of drug discovery and clinical development. Our Scientific Board is composed of scientific experts from independent organizations such as universities and governmental research institutes.
Jose Manuel Mas (MSc, PhD), Founder and CEO
José Manuel Mas is a Founder and CEO at Anaxomics Biotech. He was previously the EU Head of Collaborative Research Department at RPS Inc. (2008-2012) and he was the co-Founder and during 10 years the Chief Techology Officer at Infociencia (1998-2008). José Manuel has a degree in Biochemistry, a Master’s degree in Biotechnology and a Phd in Biocomputing, specializing in protein structure, drug design and systems biology. He has a wide experience in the development of biocomputational tools and artificial intelligence techniques.
Laura Artigas (MSc), COO
Laura Artigas is the COO at Anaxomics Biotech SL. She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology. Previously she belonged to research team of the Molecular Biology and Biochemistry Research Center for Nanomedicine of Hospital de de la Vall d' Hebrón de Barcelona, Spain. Laura has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).
Mireia Coma (MSc, PhD), Medical Director
Mireia Coma is the Business Unit Manager and the Head of Molecular Physiology at Anaxomics Biotech SL. She has a degree in Biochemistry, MSc in Experimental Biochemistry and Ph.D. in Health and Life Science. Previously she was a research Fellow at the Memory Unit of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain and at MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. She has a wide experience in preclinical testing for neurodegenerative diseases. As a part of her task in Anaxomics, she is in charge of Anaxomics Consulting Services and drug repositioning pipeline in neurodegenerative diseases.
Judith Farrés (MSc, PhD), Head of Collaborative Research
Judith Farrés is the Head of Collaborative Research at Anaxomics. She holds a degree in Biochemistry and a Master’s degree and a PhD in Biotechnology. She was previously research fellow at the Institute of Biotechnology ETH Zürich for 6 years and EU project manager assistant at UAB Barcelona for 2 years. Since 2009 she is leading the research and innovation in Anaxomics, the application of biocomputational tools based on systems biology to different pathological backgrounds.
Cristina Segu (MSc), Head of Project Management (HPM)
Cristina Segú is the Head of Project Management at Anaxomics Biotech SL. She has a degree in Biotechnology, and is MSc in Biological Anthropology. She performed her master thesis with the research team of the Pathological Anatomy Service of Germans Trias Hospital in Badalona, Spain. Cristina has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).
Raquel Valls (MSc), Senior Project Manager & Team Coordinator
Raquel Valls is a Project Manager in the Molecular Health Department of Anaxomics Biotech SL. She has a degree in Biotechnology and Biochemistry and has broad experience in project management of R&D projects focused on Medical Sciences. She has advanced skills in managing molecular biology databases to transfer the relevant information into compatible formats for subsequent bioinformatics analyses.
Professor Joan Bigorra
Currently Director of Innovation at Hospital Clínic de Barcelona, Scientific Director of the Master in Leadership and Management of Science and Innovation (UB, UAB,UPF Interuniversity program, Barcelona), Former Managing Director of Fundació Clínic per a la Recerca Biomèdica(2006-2008), Managing Director of Novartis Pharma Spain (2004-2006), COO of Novartis Pharma Spain (1997-2004). Several key positions in R&D management in other leading Pharma Industries (Sandoz Pharma, Boehringuer Ingelheim, Bayer, Esteve) (1985-1997), MBA by IESE Corporate training in General Management and Finance at Harvard Business School (1999-2003), Assistant Editor of The Lancet (Spanish edition) (1986-1996). More than 50 publications / book chapters on R&D management and health outcomes research.
Professor Xavier Gomis
Dr. Gomis-Rüth studied organic chemistry at the Chemical Institute of Sarrià (IQS, Barcelona, Spain) and he obtained his B.Sc. (1988) and M.Sc. (1989) there before moving to the Max-Planck-Institute of Biochemistry (MPIB, Martinsried, Germany), where he made his Ph.D. in protein crystallography in the lab of 1988-Nobel laureate Robert Huber (1992).
Postdoctoral stays at the Autonomous University of Barcelona (Spain), the MPIB, and the Molecular Biology Institute of Barcelona (IBMB) of the Spanish Research Council (CSIC) followed before he got a tenured Assistant Professor position at the latter institution.
Since 2008, he is Research Professor CSIC, Director of the Department of Structural Biology of the IBMB, and Head of the Proteolysis Lab at the IBMB, which is located at the premises of the Barcelona Science Park (PCB).
The Proteolysis Lab currently encompasses nine researchers and is centered on the study of proteins by molecular and structural biology to ascertain structure-function relationships following an experimental approach.
Professor Xavier Daura
Dr. Xavier Daura is Research Professor at the Catalan Institution for Research and Advanced Studies (ICREA) and Principal Investigator of the group for Computational Biology in the Institute of Biotechnology and Biomedicine (IBB) of Universitat Autònoma de Barcelona (UAB). He is BSc in Biological Sciences MSc in Biotechnology and PhD in Biological Sciences by UAB, and was a postdoctoral researcher for six years at the Swiss Federal Institute of Technology (ETH) in Zurich. The main focus of his current research is in the development of new strategies to combat bacterial infections, combining a range of computational and experimental techniques for the identification of candidate bacterial components for synthetic vaccines and antimicrobial targets with new modes of action. Dr Daura has authored over 80 publications, receiving more than 4300 citations.
Professor Baldomero Oliva
Baldo Oliva (M). Full professor of Structural Biology at the University Pompeu Fabra (UPF). Senior investigator in UPF since 2001. Doctor from UAB (1992), with research stays in Uppsala University, Imperial Cancer Research Fund (London), Rockefeller University (New York), EMBL(Heidelberg) and Leloir Institute (Buenos Aires). Technical director of Bioinformatic services in UAB between 1993 and 2000. Vice-dean of the School of Life and Health Sciences (UPF) between 2005-2010. Secretary of the Department of Experimental and Health sciences (UPF) between 2010-2015. Author of more than 120 peer reviewed articles published in journals included in SCI and 8 book chapters. Director of 12 doctoral theses and several master theses. Principal Investigator of several projects granted by the spanish government, project co-leader in EraSysBio+ grant (SHIPREC). Co-participant of 2 patents (in EU and USA). Member of Editorial Boards of BMC Bioinformatics and PLoS ONE.